CLASS II Drug recall · Reported 6 Dec 2017 · FDA Enforcement Report
No.1 Faiza Beauty Cream recalled by New Reliance Trading
New Reliance Trading is recalling No.1 Faiza Beauty Cream, distributed in New York. The recall was initiated on 6 Oct 2017 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0095-2018
- FDA event ID
- 78304
- Recalling firm
- New Reliance Trading, Maspeth, NY
- Classification
- Class II
- Status
- Terminated
- Recall initiated
- 6 Oct 2017
- FDA classified
- 25 Nov 2017
- Reported
- 6 Dec 2017
- Type
- Voluntary: Firm initiated
- Customers notified by
- Letter
- Reason category
- Other Reasons
- Drug class
- Creams, Ointments & Gels
Timeline
| 6 Oct 2017 | Recall initiated by company | |
| 25 Nov 2017 | Classified by FDA | +50 days |
| 6 Dec 2017 | Published in enforcement report | +11 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Marketed Without an Approved NDA/ANDA
Product as listed by the FDA
No.1 Faiza Beauty Cream Manufactured by: Poonia Brothers (Pak), Gujranwala, Distributed by NEW RELIANCE TRADING, INC., 5563 59th St., Maspeth, New York, 11378-2358, UPC 8993138993349, 5842109854239.
Where it was distributed
NY
Questions about this recall
Is No.1 Faiza Beauty Cream recalled?
Yes. New Reliance Trading recalled No.1 Faiza Beauty Cream on 6 Oct 2017. The recall is Class II and its status is Terminated. Recall number D-0095-2018.
Why was it recalled?
Marketed Without an Approved NDA/ANDA
Which lots are affected?
UPC 8993138993349, 5842109854239
Where was it sold?
NY
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.